CLINICAL TRIAL: PHASE III, ICA-17043 WITH OR WITHOUT HYDROXYUREA IN SICKLE CELL

临床试验：III 期，ICA-17043 在镰状细胞中含或不含羟基脲

• 批准号: 7716822
• 负责人: Kenneth I Ataga
• 金额: $ 0.14万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-02 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716822
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Effectiveness; Funding; Grant; Institution; Pain; Patients; Pharmaceutical Preparations; Phase III Clinical Trials; Purpose; Research; Research Personnel; Resources; Safety; Sickle Cell; Source; United States National Institutes of Health; hydroxyurea; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine the safety and effectiveness of the experimental drug called ICA-17043 in sickle cell patients who have two or more pain crises per year.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的目的是确定每年患有两个或更多疼痛危机的镰状细胞患者中称为ICA-17043的实验药物的安全性和有效性。